Mylan Pharmaceuticals Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Mylan Pharmaceuticals Private Limited Pharmaceutical Export Portfolio Dataset — 2 Products, $900.0K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Mylan Pharmaceuticals Private Limited — Pharmaceutical Exporter Profile (2026) | 2 Products, $900.0K Trade | TransData Nexus

Mylan Pharmaceuticals Private Limited

Indian Pharmaceutical Exporter · Advanced Oncology Specialist · $900.0K Total Trade · DGFT Verified

Mylan Pharmaceuticals Private Limited is an Indian pharmaceutical exporter with a total trade value of $900.0K across 2 products in 1 therapeutic categories. Based on 18 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Bevacizumab ($650.0K), Trastuzumab ($250.0K), .

Mylan Pharmaceuticals Private Limited — Export Portfolio & Destination Treemap

Mylan Pharmaceuticals Private Limited pharmaceutical export portfolio — 2 products across 1 therapeutic categories. Source: Indian Customs (DGFT).

Who is Mylan Pharmaceuticals Private Limited? — Company Overview & Market Position

Mylan Pharmaceuticals Private Limited, established on March 3, 1997, is a private limited company headquartered in Hyderabad, Telangana, India. The company is registered under the Corporate Identification Number (CIN) U73100TG1997PTC149781. It operates as a subsidiary of Viatris, a global pharmaceutical company formed in November 2020 through the merger of Mylan N.V. and Upjohn, Pfizer's off-patent medicine division.

The authorized capital of Mylan Pharmaceuticals Private Limited is ₹120.00 crore, with a paid-up capital of ₹10.00 crore. As of July 18, 2025, the company employed approximately 3,092 professionals. The registered office is located at Plot No. 564/A/22, Road No. 92, Jubilee Hills, Hyderabad, Telangana, 500096.

What Does Mylan Pharmaceuticals Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Bevacizumab$650.0K 2Trastuzumab$250.0K

Product Portfolio — Top 2 by Export Value

Mylan Pharmaceuticals Private Limited exports 2 pharmaceutical products across 1 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Bevacizumab	Advanced Oncology	$650.0K	13	1.4%	7
2	Trastuzumab	Advanced Oncology	$250.0K	5	0.3%	11

Mylan Pharmaceuticals Private Limited exports 2 pharmaceutical products across 1 therapeutic categories with a total export value of $900.0K. The top category is Advanced Oncology (100.0% of portfolio), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Mylan Pharmaceuticals Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Mylan Pharmaceuticals Private Limited operates manufacturing facilities in India, including a plant in Nashik, Maharashtra, which produces finished-dosage-form antiretroviral (ARV) products. This facility has been subject to Good Manufacturing Practices (GMP) inspections by several leading regulatory authorities, including the U.S. Food and Drug Administration (FDA). Additionally, the company has a manufacturing plant located at Plot No. 1-A/2, MIDC, Industrial Area, Taloja, Panvel Raigarh, Maharashtra, 410208.

3Key Leadership

As of July 18, 2025, the key leadership at Mylan Pharmaceuticals Private Limited includes:

Praveen Singh Chauhan – Whole-Time Director, appointed on April 16, 2024.

Ajay Singh Rathore – Whole-Time Director, appointed on June 21, 2019.

Rekha Lakhotiya – Company Secretary, appointed on December 3, 2015.

These leaders are responsible for overseeing the company's operations and strategic direction.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Mylan Pharmaceuticals Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Mylan Pharmaceuticals Private Limited has a significant presence in regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company's manufacturing facilities, such as the one in Nashik, Maharashtra, have been inspected and approved by the U.S. FDA, ensuring compliance with stringent regulatory standards. Additionally, Mylan has received marketing authorization from the Drug Controller General of India (DCGI) for various products, including antiretroviral drugs like Avonza™ (TLE400), a fixed-dose combination for HIV/AIDS treatment. These approvals facilitate the company's market access and distribution in these regions.

2Emerging Markets

Mylan Pharmaceuticals Private Limited has expanded its footprint in emerging markets, particularly in Africa, Latin America, and Southeast Asia. The company's partnership with Gilead Sciences to distribute Sovaldi® and Harvoni® in India exemplifies its commitment to addressing public health challenges in these regions. Furthermore, Mylan's manufacturing facilities have been subject to inspections by the World Health Organization (WHO), ensuring compliance with international standards and facilitating access to these markets.

3Geographic Strategy

Mylan Pharmaceuticals Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Mylan Pharmaceuticals Private Limited's manufacturing facilities, such as the one in Nashik, Maharashtra, have been inspected and approved by the U.S. FDA. This approval ensures that the company's products meet the stringent quality standards required for the U.S. market. Additionally, the company's manufacturing plant located at Plot No. 1-A/2, MIDC, Industrial Area, Taloja, Panvel Raigarh, Maharashtra, 410208, is registered with the FDA, indicating compliance with U.S. regulatory requirements.

2WHO & EU GMP

Mylan Pharmaceuticals Private Limited's manufacturing facilities have been subject to inspections by the World Health Organization (WHO), ensuring compliance with international Good Manufacturing Practices (GMP). This compliance facilitates the company's access to global markets and underscores its commitment to maintaining high-quality standards. Additionally, the company's manufacturing plant located at Plot No. 1-A/2, MIDC, Industrial Area, Taloja, Panvel Raigarh, Maharashtra, 410208, is registered with the European Medicines Agency (EMA), indicating adherence to EU GMP standards.

3CDSCO & Indian Regulatory

Mylan Pharmaceuticals Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Mylan Pharmaceuticals Private Limited operates in a competitive landscape, particularly in the oncology and antiretroviral (ARV) segments. In the oncology segment, the company exports Bevacizumab and Trastuzumab, with export values of $650K and $250K, respectively. These products hold market shares of 1.4% and 0.3%, ranking 7th and 11th in their respective categories. The company's portfolio concentration is high, with the top five products accounting for 100% of its exports. This indicates a focused approach but also exposes the company to risks associated with over-reliance on a limited product range.

2Key Differentiators

Mylan Pharmaceuticals Private Limited's key differentiators include its strong presence in the oncology and ARV segments, with a focused product portfolio that allows for specialized expertise and operational efficiencies. The company's compliance with international regulatory standards, such as WHO GMP and EU GMP, enhances its credibility and facilitates access to global markets. Additionally, its strategic partnerships, such as the exclusive agreement with Gilead Sciences to distribute Sovaldi® and Harvoni® in India, demonstrate its commitment to addressing significant public health challenges.

3Strategic Position

Buyer Due Diligence Brief — Evaluating Mylan Pharmaceuticals Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Mylan Pharmaceuticals Private Limited has a track record of exporting finished pharmaceutical formulations, with a total export value of $900K USD across 18 shipments. The company's focus on oncology and ARV products, with a high portfolio concentration, indicates specialized expertise and operational efficiencies. The absence of publicly available records indicating regulatory issues, such as Form 483 observations or warning letters, suggests reliability in its manufacturing processes. However, the high portfolio concentration may pose risks related to market fluctuations and regulatory changes affecting specific product categories.

2Certifications to Verify

Importers should verify the following certifications to ensure product quality and regulatory compliance:

TransData Nexus Research · FDA, WHO, EMA regulatory databasesMar 2026

Frequently Asked Questions — Mylan Pharmaceuticals Private Limited

How many pharmaceutical products does Mylan Pharmaceuticals Private Limited export from India?

Mylan Pharmaceuticals Private Limited exports 2 pharmaceutical products across 1 therapeutic categories. The top exports are Bevacizumab ($650.0K), Trastuzumab ($250.0K). Total export value is $900.0K.

What is Mylan Pharmaceuticals Private Limited's total pharmaceutical export value?

Mylan Pharmaceuticals Private Limited's total pharmaceutical export value is $900.0K, based on 18 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Mylan Pharmaceuticals Private Limited cover?

Mylan Pharmaceuticals Private Limited exports across 1 therapeutic categories. The largest are Advanced Oncology (100.0%, 2 products).

Get Full Mylan Pharmaceuticals Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.